Across TCGA pan-cancer cohorts, TMEM116 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM116 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM116 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM116 expression acts as an unfavorable survival marker.

HNSC, KIRP, and STAD are the cancer types where TMEM116 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.233	0.662	.003	18	view →
KIRP	OS	Median	All	0.135	0.703	.002	12	view →
STAD	OS	Median	All	0.199	0.730	.002	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TMEM116 tumor-vs-normal RNA expression · all TMEM116 data types